REFERENCES
- French HIV therapy guidelines, 2006. Available at: http://www.sante.gouv.fr/htm/actu/yeni_sida/rapport_experts_2006.pdf. Accessed March 21,2007.
- Stek A, Mirochnick M, Capparelli E, et al. Reduced lopina-vir exposure during pregnancy: preliminary pharmacoki-netic results from PACTG 1026. In: Program and abstracts of the XVth International AIDS Conference; July 11–16, 2004; Bangkok, Thailand. Abstract LbOrB08.
- Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS. 2007;21: 643–647.
- Mirochnik M, Stek A, Capparelli E, et al. Adequate lopinavir exposure achieved with higher dose during the third tri-mester of pregnancy. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, Colorado. Abstract 710.
- Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailibility to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminushed food effect. J Acquir Immune Defic Syndr 2007;44:401–410.